• Triamcinolone B1859: Practical Research Guide

  2026-08-22

  Triamcinolone B1859 provides a defined synthetic glucocorticoid agonist for controlled studies of glucocorticoid receptor signaling, inflammation, and immunosuppression. This dossier-led guidance addresses preparation, storage, assay controls, and troubleshooting; the compound is for scientific research only and should not be used diagnostically, therapeutically, or clinically.

• Hypoxia, Choroid Plexus, and Cognitive Impairment

  2026-08-22

  This mouse study identifies choroid plexus barrier disruption and M1 macrophage polarization as central links between simulated high-altitude hypoxia and cognitive dysfunction. Its main contribution is a mechanistic cascade connecting aberrant AMPK signaling and oxidative stress to neuroimmune barrier failure, providing a framework for studying hypoxia-related CNS injury without reducing the problem to neuronal metabolism alone.

• Mubritinib–HSA Binding: Mechanistic Evidence

  2026-08-21

  The 2023 reference study combines multispectroscopic analysis, biochemical testing, and molecular docking to define how mubritinib binds human serum albumin. Its findings connect moderate, site-I binding with fluorescence, structural, and esterase-like functional changes that may influence mubritinib disposition and pharmacological interpretation.

• NLRP3-Driven Astrocyte States in Morphine Tolerance

  2026-08-20

  The 2024 Frontiers in Pharmacology study links NLRP3 inflammasome activation with a shift in spinal astrocytes toward an A1-like reactive phenotype during morphine tolerance. Its intrathecal morphine model and MCC950 intervention suggest that inflammasome-associated astrocyte remodeling is a modifiable component of opioid tolerance, while leaving cell-specific causality and clinical transferability open for further study.

• Resveratrol, Smad Signaling, and GBM Invasion

  2026-08-20

  The reference study shows that resveratrol suppresses TGF-β1-induced epithelial–mesenchymal transition, migration, invasion, and stem-like properties in glioblastoma models through Smad-dependent signaling. Its integrated use of molecular, functional, stemness, and xenograft assays provides a framework for linking TGF-β pathway activity with invasive behavior, while also highlighting the limits of translating a natural-compound response into clinical therapy.

• Extracellular Vesicle Inhibition in TNBC

  2026-08-19

  McNamee and colleagues systematically tested pharmacological strategies for suppressing extracellular vesicle release from triple-negative breast cancer cells. Their results indicate that multiple EV subpopulations contribute to aggressive cell-to-cell signaling and that substantial, rather than partial, release inhibition may be required to limit functional effects on recipient cells.

• WNT Signaling in Obstructed Extrahepatic Bile Ducts

  2026-08-19

  Calder and colleagues show that WNT signaling is an active component of the extrahepatic bile duct response to obstruction, rather than a pathway restricted to developmental biology or intrahepatic injury. Using bile duct ligation, organoids, explants, pharmacologic perturbation, and transcriptomics, the study links cholangiocyte-derived WNT ligands, β-catenin activity, and proliferative repair.

• Cyclosporin A as a Translational Mechanism Probe

  2026-08-18

  Cyclosporin A is more than a classic immunosuppressant: it is a pathway-resolved probe spanning cyclophilin–calcineurin–NF-AT signaling, p38 MAPK activity, and mitochondrial permeability transition. This thought-leadership guide shows how translational researchers can use Cyclosporin to distinguish target engagement from downstream phenotype while avoiding overinterpretation across immunology, mitochondrial biology, and neuroscience.

• Mechanisms of Cell Death in Heart Disease

  2026-08-18

  Konstantinidis, Whelan, and Kitsis synthesize evidence showing that cardiac injury involves not only apoptosis and passive necrosis, but also regulated forms of necrotic death connected through overlapping signaling pathways. The review is important for experimental design because it links cell morphology, ATP status, death-receptor signaling, mitochondria, and the endoplasmic reticulum while emphasizing that therapeutic inhibition of cell death requires careful definition of the death mechanism.

• p-Cresyl Sulfate and Aortic Valve Calcification

  2026-08-17

  The reference study identifies p-Cresyl sulfate as a driver of calcification in aortic valvular interstitial cells and connects this effect to HIF-1α activation, klotho loss, NF-κB acetylation, and RUNX2 induction. Its combined porcine-cell and rat CKD-model design supports klotho and SIRT1-linked signaling as experimentally testable targets in calcific aortic valve disease.

• SB-505124 Hydrochloride in Cancer Mechanobiology

  2026-08-17

  SB-505124 hydrochloride provides a reversible way to separate TGF-β/activin signaling from ion channel–regulated cancer cell mechanics. This article presents a practical, multi-readout strategy linking Smad signaling, stiffness, and immune-cell susceptibility without overstating the current evidence.

• ERAD Hijacking for Transmembrane Protein Degradation

  2026-08-16

  The reference study introduces ERAD-engaging chimeras (ERADECs), a targeted protein degradation platform that redirects endoplasmic-reticulum-associated degradation toward transmembrane proteins. Its desonide-based PD-L1 degraders achieved sub-nanomolar activity and stronger tumor suppression than a clinically used PD-L1 antibody in vivo, establishing a mechanistic framework for expanding degradation beyond conventional cytosolic and lysosomal routes.

• Maternal IL-17A and Neonatal GBS Disease Risk

  2026-08-15

  This prospective mother–newborn study links reduced maternal IL-17A responses with invasive Group B Streptococcus disease in newborns. By combining cytokine profiling with ex vivo pathogen-recognition receptor stimulation, it identifies maternal IL-17A as a promising risk-stratification biomarker while highlighting the limits of using colonization status alone.

• TAK1–YAP Signaling in Gastric Cancer Stem Cells

  2026-08-14

  The reference study identifies TGFβ-activated kinase 1 (TAK1) as a regulator of gastric cancer stem-cell self-renewal and oncogenesis. Its proposed mechanism links IL-6–dependent TAK1 elevation to cytoplasmic YAP stabilization and increased SOX2 and SOX9 transcription, providing a mechanistic framework for studying gastric cancer stemness.

• A 83-01 for Biliary Injury Signaling Studies

  2026-08-14

  A 83-01 is an ALK-5 inhibitor that enables mechanistic dissection of TGF-β responses in biliary organoids and injury models. This article connects its pharmacology with new evidence on WNT-dependent extrahepatic bile duct proliferation while defining assay controls, interpretation limits, and practical handling.

8374 records 1/559 page Next 12345 下5页 Last page